|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:advocacy
|
required before treatment
|
|
gptkbp:approves
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:2002
gptkb:juvenile_idiopathic_arthritis
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
psoriasis
|
|
gptkbp:biosimilar_available
|
gptkb:Yes
|
|
gptkbp:brand
|
gptkb:adalimumab
|
|
gptkbp:class
|
gptkb:immunotherapy
|
|
gptkbp:clinical_trial
|
worldwide
Phase III
|
|
gptkbp:clinical_use
|
long-term treatment
|
|
gptkbp:developed_by
|
gptkb:Abb_Vie
|
|
gptkbp:dosage_form
|
every two weeks
weekly for some conditions
|
|
gptkbp:drug_form
|
pre-filled syringe
pen injector
|
|
gptkbp:drug_interactions
|
may occur with other immunosuppressants
|
|
gptkbp:financial_support
|
available for users
|
|
gptkbp:formulation
|
solution for injection
|
|
gptkbp:generic_availability
|
not available yet
|
|
gptkbp:healthcare
|
gptkb:Yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Humira
|
|
gptkbp:indication
|
autoimmune diseases
|
|
gptkbp:ingredients
|
gptkb:adalimumab
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:marketed_as
|
over 100 countries
various brand names
|
|
gptkbp:mechanism_of_action
|
TNF inhibitor
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:patient_education
|
important for proper use
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:pharmacokinetics
|
reduces inflammation
modulates immune response
half-life of 15 days
|
|
gptkbp:price
|
highly priced medication
|
|
gptkbp:provides_guidance_on
|
recommended in treatment protocols
|
|
gptkbp:research_focus
|
gastrointestinal diseases
autoimmune disorders
chronic inflammatory diseases
dermatological conditions
pediatric conditions
rheumatological conditions
|
|
gptkbp:route_of_administration
|
subcutaneous injection
|
|
gptkbp:safety_measures
|
required during treatment
|
|
gptkbp:sales
|
over $20 billion annually
highest-selling drug
|
|
gptkbp:side_effect
|
headache
nausea
heart failure
increased risk of infections
injection site reactions
serious infections
liver problems
malignancies
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:symbolism
|
gptkb:Yes
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:bfsParent
|
gptkb:Abb_Vie
|
|
gptkbp:bfsLayer
|
4
|